Nymox says data supports Alzheimer's disease test, get $15m for BHP
This article was originally published in Clinica
A paper published in the January 2008 issue of Expert Review of Molecular Diagnostics concludes that Nymox Pharmaceutical's AlzheimAlert urine test "adds significant useful information in the diagnosis of Alzheimer's disease particularly for the family physician". The FDA has repeatedly refused to grant US marketing authorisation for the test, which detects strands of neural thread protein in urine (see Clinica No 1168, p 20). Nymox markets the test in Europe and offers it in the US as a CLIA-certified diagnostic service. Separately, the company said it had secured $15m in financial commitments. Nymox said it will use the funds to develop its NX-1207 drug for benign prostate hyperplasia and other new products.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.